Home › Funds › D. E. Shaw & Co › BSX
D. E. Shaw & Co position in BSX
BOSTON SCIENTIFIC CORP · Health Care
D. E. Shaw & Co reported holding 27,267,209 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$1.16B, representing 0.61% of its reported portfolio and ranking #24 among its reported holdings. D. E. Shaw & Co has disclosed BSX holdings in 20 of the last 20 reported quarters, going back to Q3 2021.
Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR
How D. E. Shaw & Co's BSX position evolved
D. E. Shaw & Co first disclosed a stake in BSX in Q3 2021 at 337,953 shares (US$14.7M). The position peaked in Q1 2026 at 24,432,352 shares, worth US$1.53B. Across 20 filings, D. E. Shaw & Co increased the stake 11 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 27,267,209 shares valued at US$1.16B — an increase of 2,834,857 shares quarter over quarter.. Notable position changes include a 337% increase in Q4 2021 (shares rose 4% over the following quarter), a 358% increase in Q2 2022 (shares rose 4% over the following quarter), a 376% increase in Q1 2025 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 337.95K | $14.66M | New |
| Q4 2021 | 1.48M | $62.73M | Add |
| Q1 2022 | 584.22K | $25.88M | Reduce |
| Q2 2022 | 2.68M | $99.77M | Add |
| Q3 2022 | 1.82M | $70.57M | Reduce |
| Q4 2022 | 827.13K | $38.27M | Reduce |
| Q1 2023 | 471.75K | $23.60M | Reduce |
| Q2 2023 | 1.17M | $63.06M | Add |
| Q3 2023 | 1.14M | $60.06M | Reduce |
| Q4 2023 | 519.45K | $30.03M | Reduce |
| Q1 2024 | 1.40M | $95.80M | Add |
| Q2 2024 | 882.73K | $67.98M | Reduce |
| Q3 2024 | 1.82M | $152.93M | Add |
| Q4 2024 | 832.40K | $74.35M | Reduce |
| Q1 2025 | 3.96M | $399.85M | Add |
| Q2 2025 | 6.88M | $738.78M | Add |
| Q3 2025 | 8.94M | $872.85M | Add |
| Q4 2025 | 11.25M | $1.07B | Add |
| Q1 2026 | 24.43M | $1.53B | Add |
| Q2 2026 | 27.27M | $1.16B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 19 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), Janus Henderson Group (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- Banque Cantonale Vaudoise 67.61K sh · $2.89B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 50.52M sh · $2.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
- Bollard Group LLC 18.42M sh · $786.20M · Q2 2026
More on D. E. Shaw & Co
FAQ
How long has D. E. Shaw & Co held BSX?
D. E. Shaw & Co has disclosed BSX holdings in 20 of the last 20 reported quarters, going back to Q3 2021.
What is D. E. Shaw & Co's current position in BSX?
As of Q2 2026, D. E. Shaw & Co holds 27.27M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.16B, representing 0.61% of its reported portfolio and ranking #24.
Has D. E. Shaw & Co been buying or selling BSX?
In the latest 13F filing (Q2 2026), D. E. Shaw & Co increased its position in BSX. The position peaked in Q1 2026 at 24.43M shares.
Which other funds hold BSX?
Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, Janus Henderson Group, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.